Featured News

On August 29, 2019, the Celiac Disease Foundation’s 7th Annual New York Golf Outing was held at the New York Country Club in New Hempstead, NY.

CEO Marilyn G. Geller speaks at the 18th International Celiac Disease Symposium (ICDS).

ActoBio announces FDA has given permission to an Investigational New Drug (IND) application for Actobiotics® AG017, a therapeutic candidate for celiac disease.

Julie McCormack discusses her annual AITI Golf Outing and why she continues to be a Celiac Disease Foundation top Team Gluten-Free fundraiser.

Often, when a patient is following a long-term gluten-free diet with good compliance, micronutrient deficiencies cannot be detected. This review - published in the scientific journal Medicina - evaluates the most recent literature on micronutrient deficiencies in patients following a long-term gluten-free diet in order to provide dietary supplementation advice. The study concludes that in patients with micronutrient deficiencies caused by celiac disease, vitamin supplements may be necessary.

The Celiac Disease Foundation is proud to announce that Bradley J. Herrema, Secretary of the Foundation’s Board of Directors, has been selected for recognition as one the 2020 Best Lawyers in America.

A study published by the Journal of the American Medical Association (JAMA) concluded that higher gluten intake during the first 5 years of life is correlated with an increased risk of celiac disease among children who possess the HLA genes associated with celiac disease. The study was conducted in research centers in the United States, Finland, Germany, and Sweden.

The Celiac Disease Foundation was proud to be an endorsement partner of the 2019 James W. Freston Conference – Food at the Intersection of Gut Health and Disease to educate physicians on the latest research on celiac disease management. On August 9-10, 2019, Director of Research and Advocacy, Julia McBeth, attended the conference in Chicago,…

On August 13th, 2019, Innovate Biopharmaceuticals, Inc. (Innovate) announced the first patient has been dosed in its Phase 3 clinical trial for patients with celiac disease. The CeD LA 3001 trial is testing larazotide acetate—also known as INN-202—as an adjunct treatment for patients with celiac disease still experiencing symptoms on a gluten-free diet. Larazotide acetate…

Proud Sponsor Enjoy Life has partnered with the Celiac Disease Foundation to make a positive impact this Back-to-School season.